Charlée Nardin
Charlée Nardin is an expert in Dermatology at Centre Hospitalier Universitaire de Besançon (France). As of October 2026, ScienceLeadR ranks Charlée Nardin in the top 1% of experts worldwide for Skin Neoplasms. Charlée Nardin has authored 152 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 594 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Neurology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2014 - 2026
Number : 152
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). PMID 42372635 — melanoma, neoplasms, cohort studies, therapeutics | Eur J Cancer | 2026 | 0 |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma. PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines | Ann Oncol Top journal | 2026 | 0 |
| Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA. PMID 41806521 — cells, safety, carcinoma, squamous cell, neoplasms, therapeutics | Eur J Cancer | 2026 | 0 |
| Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. PMID 41396687 — skin, cells, safety, melanoma, neoplasms, sarcoma, immune checkpoint inhibitors, hiv, therapeutics, skin neoplasms | Oncologist | 2025 | 0 |
| Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years. PMID 41055628 — cells, safety, carcinoma, squamous cell, immunotherapy, drug-related side effects and adverse reactions, immune checkpoint inhibitors, dermatology, skin neoplasms, cutaneous squamous cell carcinoma | J Am Acad Dermatol | 2025 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Predicting Response to Anti PD 1 PD L1 Immunotherapy by Plasma Extracellular Vesicle Analysis NCT07376512 — skin, cells, extracellular vesicles, lung, melanoma, neoplasms, carcinoma, non-small-cell lung, biomarkers, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, plasma, skin neoplasms, carcinoma | N/A | Not yet recruiting | 2026 |
| Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri scar Dermatoheliosis as a Predictive Factor of Response to Anti PD 1 NCT05856565 — skin, intelligence, cicatrix, melanoma, neoplasms, algorithms, immunotherapy, photography, therapeutics, artificial intelligence | N/A | Recruiting | 2023 |
| Personalized Circulating DNA Follow up in Melanoma (PERCIMEL) NCT04866680 — blood, melanoma, immunotherapy, therapeutics, tissues | N/A | Active not recruiting | 2023 |
LeadR Networks
Main global connection map